DURECT CORP. overview

DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million PR Newswire CUPERTINO, Calif., Nov. 25, 2024 CUPERTINO, Calif. , Nov. 25, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announced the sale of its ALZET ® line of osmotic pumps to Lafayette...

DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update PR Newswire CUPERTINO, Calif., Nov. 13, 2024 - Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation - Webcast of Earnings Call Today, November 13 at 4:30 p.m. ET CUPERTINO, Calif. , Nov. 13, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2024 and...

DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update PR Newswire CUPERTINO, Calif., Nov. 6, 2024 CUPERTINO, Calif. , Nov. 6, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its third quarter financial results on...

DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024 PR Newswire CUPERTINO, Calif., Oct. 17, 2024 CUPERTINO, Calif. , Oct. 17, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announce that it will deliver an oral and two poster presentations at The Liver Meeting 2024 ,...

DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis PR Newswire CUPERTINO, Calif., Sept. 25, 2024 - Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design - Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint; topline results expected within two years of trial initiation - Protocol for Phase 3 trial builds on data...

DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference PR Newswire CUPERTINO, Calif., Sept. 4, 2024 CUPERTINO, Calif. , Sept. 4, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced management's participation in the H.C. Wainwright 26 th Annual Global...

DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update PR Newswire CUPERTINO, Calif., Aug. 13, 2024 - FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis - Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Design - Seeking to Initiate Phase 3 Trial in 2024 with Topline Results Expected in 2H 2026 - Webcast of Earnings Call Today, August 13th at 4:30 p.m. ET CUPERTINO, Calif. , Aug. 13, 2024 /PRNewswire/ --...

DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update PR Newswire CUPERTINO, Calif., Aug. 7, 2024 CUPERTINO, Calif. , Aug. 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its second quarter...